|
Post by mnkdfann on Dec 24, 2019 10:34:03 GMT -5
I cannot view the article (a pay wall is up). Did the big O give a price target? If so, what is it?
|
|
|
Post by cretin11 on Dec 24, 2019 12:51:14 GMT -5
I cannot view the article (a pay wall is up). Did the big O give a price target? If so, what is it? I believe it’s an Outperform rating but no price target.
|
|
|
Post by jcastle on Dec 26, 2019 17:14:43 GMT -5
Price Target $2.50. That's 31% upside. MannKind initiated with an Outperform at Oppenheimer Oppenheimer analyst Steven Lichtman initiated coverage of MannKind with an Outperform rating and $2.50 price target. Read more at: thefly.com/landingPageNews.php?id=3010564
|
|
|
Post by brotherm1 on Dec 26, 2019 18:29:25 GMT -5
I’m guessing the website is not credible. No date. The analyst is not listed on MNKD’s website. $2.50 would be more like a 90% gain.
|
|
|
Post by mytakeonit on Dec 26, 2019 18:31:33 GMT -5
Looks like old news from May 14th.
But, that's mytakeonit
|
|
|
Post by babaoriley on Dec 26, 2019 18:40:47 GMT -5
You wanna see old news, look at the first several posts in this thread back in June of 2014!!
|
|
|
Post by cretin11 on Dec 26, 2019 20:12:52 GMT -5
You wanna see old news, look at the first several posts in this thread back in June of 2014!! Holy cow, price target: $16 And as some of us old timers remember, that means price target $80 by today’s dollars.
|
|
|
Post by Clement on Dec 27, 2019 9:03:19 GMT -5
|
|
|
Post by ktim on Dec 27, 2019 12:15:57 GMT -5
You wanna see old news, look at the first several posts in this thread back in June of 2014!! Holy cow, price target: $16 And as some of us old timers remember, that means price target $80 by today’s dollars. To protect the horrendously incompetent we should avoid mentioning the name of whoever said that.
|
|
|
Post by novafett on Jan 9, 2020 10:07:03 GMT -5
Not to stir the pot but what ever happened to Adam F's coverage of MNKD? Don't really want to hear from him again but he's kind of like Martin Shkreli, a weasley, love to hate, germ.
|
|
|
Post by mnkdfann on Jan 9, 2020 10:24:01 GMT -5
Not to stir the pot but what ever happened to Adam F's coverage of MNKD? Don't really want to hear from him again but he's kind of like Martin Shkreli, a weasley, love to hate, germ. I believe he mostly moved on to more interesting (at least for him) subjects and stocks to write about. And, anyway, my understanding is that most of what he writes these days is behind a pay wall at STAT and I assume few, if any, of us here subscribe. See: www.statnews.com/staff/adam-feuerstein/However, coincidentally, I just saw a 20 year review article about the J.P. Morgan Healthcare Conference at STAT that was published today and is open to the public, with AF listed as one of several co-authors, and Mannkind and Al Mann get a very brief mention under the 2011 conference year memories. Really, it is at least as much about Shkreli: www.statnews.com/2020/01/09/jp-morgan-conference-20-years-look-back/"2011: Shkreli vs. a billionaire Before Martin Shkreli was getting in trouble with the general public, he was taunting billionaires. In 2011, he picked a fight with MannKind founder and CEO Al Mann during the latter’s breakout session with investors. Shkreli was shorting MannKind stock at the time. Tempers flared. Insults were exchanged."
|
|
|
Post by MnkdWASmyRtrmntPlan on Jan 21, 2020 14:14:50 GMT -5
MannKind (NASDAQ:MNKD) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday, January 10th, ValuEngine reports. A number of other equities analysts have also recently commented on MNKD. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price objective on shares of MannKind in a research report on Thursday, November 7th. Svb Leerink reaffirmed an “outperform” rating on shares of MannKind in a research report on Thursday, January 2nd. Cantor Fitzgerald began coverage on shares of MannKind in a research report on Thursday, October 24th. They set an “overweight” rating and a $3.00 price objective for the company. BidaskClub downgraded MannKind from a “buy” rating to a “hold” rating in a report on Friday, December 27th. Finally, Oppenheimer began coverage on MannKind in a report on Monday, December 23rd. They set an “outperform” rating and a $2.50 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. MannKind currently has an average rating of “Buy” and an average price target of $2.83. rivertonroll.com/news/2020/01/21/valuengine-downgrades-mannkind-nasdaqmnkd-to-sell-updated.html
|
|
|
Post by mytakeonit on Jan 21, 2020 14:21:42 GMT -5
And my FREE advice ... it's going to $100 - $200 pps in 3 - 5 years. Well, let's see if we hit that $10 mark by end of February.
But, that's mytakeonit
|
|
|
Post by cretin11 on Jun 3, 2020 21:47:49 GMT -5
And my FREE advice ... it's going to $100 - $200 pps in 3 - 5 years. Well, let's see if we hit that $10 mark by end of February. But, that's mytakeonit February of what year? Just wondering how much time we have to load up on shares.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 3, 2020 23:23:01 GMT -5
And my FREE advice ... it's going to $100 - $200 pps in 3 - 5 years. Well, let's see if we hit that $10 mark by end of February. But, that's mytakeonit February of what year? Just wondering how much time we have to load up on shares. Well you know what they say about FREE stuff......
|
|